• 1
    Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 1104
  • 2
    Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 76671
  • 3
    ACS. Cancer Facts and Figures. Atlanta: The American Cancer Society, 2006
  • 4
    Mullan RJ, Jacobsen SJ, Bergstralh EJ et al. Decline in the overall incidence of regional-distant prostate cancer in Olmsted County, MN, 1980–2000. BJU Int 2005; 95: 9515
  • 5
    Smith EB, Frierson HF Jr, Mills SE, Boyd JC, Theodorescu D. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading? Cancer 2002; 94: 22827
  • 6
    D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 96974
  • 7
    Oesterling JE, Brendler CB, Epstein JI, Kimball AW Jr, Walsh PC. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 1987; 138: 928
  • 8
    Badalament RA, Miller MC, Peller PA et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996; 156: 137580
  • 9
    Moul JW, Connelly RR, Lubeck DP et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001; 166: 13227
  • 10
    Veltri RW, Miller MC, Partin AW, Poole EC, O’Dowd GJ. Prediction of prostate carcinoma stage by quantitative biopsy pathology. Cancer 2001; 91: 23228
  • 11
    Narayan P, Gajendran V, Taylor SP et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46: 20512
  • 12
    Blute ML, Bergstralh EJ, Partin AW et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 2000; 164: 15915
  • 13
    Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 144551
  • 14
    Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 8438
  • 15
    Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003; 62: 86671
  • 16
    Thompson IM, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004; 350: 223946
  • 17
    Ghani KR, Grigor K, Tulloch DN, Bollina PR, McNeill SA. Trends in reporting Gleason score 1991–2001: changes in the pathologist’s practice. Eur Urol 2005; 47: 196201